Participants in the Employee Investment Matching Program in March 2022 was entitled to receive matching shares after two years given that the participants are still employed with the Group. Please refer to note 18 in the annual report 2023 for further details.
The program is now completed and the matching shares have vested. The Board of Carasent has decided to use the right to settle the matching shares in cash. The cash settlement will be NOK 889,089 based on the closing share price at 14 March 2024.
The following primary insiders of Carasent had outstanding matching shares:
• Svein Martin Bjørnstad, CFO: 1,540 shares
• Niclas Hugosson, CPO: 1,540 shares
• Ingvild Skarestad, Country Manager: 4,621 shares
• Björn Jacobsson, CEO Medrave: 4,313 shares
For further details please contact:
Daniel Öhman, CEO Tel: +46 70-855 37 07, or
Svein Martin Bjørnstad, CFO Tel: +47 979 69 493
This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication at 2024-03-25 18:13 CET.